Evonik, Turns

Evonik Turns to Oxeno Sale as BASF Exit Leaves a 24-Euro Marker

Published on 11/21/2026 at 20:40 | Editorial boerse-global.de
Evonik says the Oxeno divestment is on track, with a buyer expected in the coming months, but the sale's economics remain unproven after BASF dropped its takeover bid.
Evonik, Turns, Oxeno, Sale, BASF, Exit, Leaves, Marker Illustration mit AI erstellt.

Evonik has told investors that the divestment of its Oxeno unit is running to schedule, with a buyer expected to be named over the coming months. The update, issued on 16 November, shifts attention to a narrower question: whether the sale can be struck on terms that actually support the standalone valuation now that takeover interest has evaporated.

That question carries more weight after BASF walked away on Thursday. The chemicals giant had made two non-binding all-cash offers for Evonik, the most recent at €24 per share, and both were rejected. BASF said the prospects and risks of an independent Evonik did not, in its view, justify a higher price. Because the bid was for the whole company, it offers no yardstick for what a buyer might pay for Oxeno alone.

Process Progress Is Not Price Discovery

Evonik's statement on the scheduled pace of the Oxeno process addresses timing, not economics. On its own it says nothing about the price a purchaser would accept, which is why the two issues deserve to be kept apart. A named buyer would make the transaction more tangible, but whether it convinces on value can only be judged once the conditions are disclosed.

The distinction matters in light of the BASF talks. Reuters reported on Wednesday, citing two people close to Evonik, that a higher offer alone would not have secured support for a takeover — a convincing industrial rationale would also have been required. That assessment concerned a full acquisition of Evonik rather than the Oxeno sale, yet it illustrates why the standalone story should not be anchored to an earlier bid price.

What a Good Outcome Would Look Like

In the best case, Evonik names a buyer within the promised window and simultaneously sets out terms that can be assessed on their merits. Investors could then weigh whether the disposal underpins the value of the standalone business. The milestone would not simply be that a buyer exists; it would be that the deal becomes measurable against concrete conditions.

Should investors sell immediately? Or is it worth buying Evonik?

Even then, a signed agreement must be separated from completion. News of a buyer could reduce uncertainty without the sale being finalised, so the positive scenario depends on which step Evonik actually reports and what conditions govern execution.

Disappointment Can Come From Either Direction

The risk is not confined to a delayed announcement. A buyer named on schedule could still leave the economics opaque: with terms undisclosed, the process would have advanced while offering little basis for valuation from the buyer's identity alone. Equally, a sale could close on conditions that fall short of investor expectations — a step forward for the divestment, but no proof of a higher value for Evonik. A delay, by contrast, would be a setback to the expected timetable rather than evidence that the sale has failed. Each scenario carries different consequences for how the shares are assessed.

The Stakeholder Dimension

Behind the deal arithmetic sits Evonik's ownership structure. RAG-Stiftung, the company's largest shareholder, said on Friday that it regretted BASF's decision to end its efforts without deeper exploratory talks between the two boards, according to Reuters. The foundation is sticking to its goal of gradually reducing its stake in Evonik to 25.1%.

Handelsblatt reported that IG BCE weighed in on Friday, calling for RAG-Stiftung's responsibilities toward Evonik to be reordered. The union criticised the foundation's dividend policy and demanded new agreements covering investment, employment, training and site security.

The Next Disclosure Is the Real Test

As long as Evonik says the Oxeno process is on track, the promised naming of a buyer in the coming months remains the next concrete checkpoint. If that step slips, so does the opportunity to assess the sale's potential contribution with any confidence. If a buyer is named without the economic parameters being laid out, what changes is the procedural status, not the foundation for valuation.

For shareholders the difference is decisive. Anyone already treating Oxeno as grounds for a higher Evonik valuation is betting on terms that cannot yet be inferred from the reported progress. Only when Evonik specifies the state of the transaction and its economic conditions can that scenario be distinguished from the mere prospect of a sale.

Ad

Evonik Stock: New Analysis - 21 November

Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evonik analysis...

Disclaimer...
en | DE000EVNK013 | EVONIK | boerse | 70543404 |